Innate Pharma Asset Resilience Ratio
Innate Pharma asset resilience ratio. Innate Pharma (IPH) has an Asset Resilience Ratio of 54.70% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Innate Pharma to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Innate Pharma (2003–2025)
Asset resilience ratio of Innate Pharma from 2003 to 2025. This chart shows how Innate Pharma's Asset Resilience Ratio has changed over time. Read Innate Pharma (IPH) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Innate Pharma's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see IPH total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €28.09 Million | 44.79% |
| Short-term Investments | €6.22 Million | 9.91% |
| Total Liquid Assets | €34.31 Million | 54.70% |
Asset Resilience Insights
- Very High Liquidity: Innate Pharma maintains exceptional liquid asset reserves at 54.70% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Innate Pharma Industry Peers by Asset Resilience Ratio
Compare Innate Pharma's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 35.16% |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294 |
Biotechnology | 23.15% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Achieve Life Sciences Inc
F:SP4P |
Biotechnology | 3.60% |
Innate Pharma Asset Resilience Ratio by Year (2003–2025)
Innate Pharma asset resilience ratio by year from 2003 to 2025. The table below shows the annual Asset Resilience Ratio data for Innate Pharma.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 54.70% | €34.31 Million ≈ $40.11 Million |
€62.72 Million ≈ $73.33 Million |
-18.02pp |
| 2024-12-31 | 72.73% | €80.77 Million ≈ $94.43 Million |
€111.06 Million ≈ $129.84 Million |
+22.53pp |
| 2023-12-31 | 50.20% | €92.46 Million ≈ $108.09 Million |
€184.19 Million ≈ $215.34 Million |
+1.37pp |
| 2022-12-31 | 48.82% | €101.48 Million ≈ $118.65 Million |
€207.86 Million ≈ $243.01 Million |
+4.02pp |
| 2021-12-31 | 44.80% | €119.84 Million ≈ $140.10 Million |
€267.50 Million ≈ $312.73 Million |
-4.53pp |
| 2020-12-31 | 49.33% | €151.64 Million ≈ $177.28 Million |
€307.42 Million ≈ $359.41 Million |
-5.21pp |
| 2019-12-31 | 54.53% | €218.87 Million ≈ $255.88 Million |
€401.36 Million ≈ $469.23 Million |
+17.40pp |
| 2018-12-31 | 37.13% | €167.53 Million ≈ $195.86 Million |
€451.22 Million ≈ $527.52 Million |
+30.56pp |
| 2017-12-31 | 6.57% | €16.74 Million ≈ $19.57 Million |
€255.02 Million ≈ $298.15 Million |
-1.17pp |
| 2016-12-31 | 7.74% | €21.78 Million ≈ $25.47 Million |
€281.58 Million ≈ $329.19 Million |
-19.41pp |
| 2015-12-31 | 27.14% | €83.04 Million ≈ $97.08 Million |
€305.96 Million ≈ $357.69 Million |
+21.68pp |
| 2014-12-31 | 5.46% | €4.95 Million ≈ $5.79 Million |
€90.69 Million ≈ $106.03 Million |
+0.11pp |
| 2013-12-31 | 5.35% | €2.99 Million ≈ $3.49 Million |
€55.88 Million ≈ $65.33 Million |
+1.14pp |
| 2012-12-31 | 4.21% | €2.03 Million ≈ $2.38 Million |
€48.30 Million ≈ $56.46 Million |
-1.55pp |
| 2010-12-31 | 5.76% | €2.76 Million ≈ $3.23 Million |
€48.01 Million ≈ $56.13 Million |
+1.48pp |
| 2009-12-31 | 4.28% | €2.75 Million ≈ $3.21 Million |
€64.22 Million ≈ $75.08 Million |
-33.43pp |
| 2008-12-31 | 37.70% | €22.95 Million ≈ $26.83 Million |
€60.86 Million ≈ $71.15 Million |
-38.78pp |
| 2007-12-31 | 76.48% | €48.30 Million ≈ $56.47 Million |
€63.15 Million ≈ $73.83 Million |
-1.01pp |
| 2006-12-31 | 77.49% | €53.66 Million ≈ $62.74 Million |
€69.25 Million ≈ $80.97 Million |
+13.87pp |
| 2005-12-31 | 63.62% | €15.76 Million ≈ $18.42 Million |
€24.77 Million ≈ $28.96 Million |
-20.59pp |
| 2004-12-31 | 84.21% | €24.85 Million ≈ $29.05 Million |
€29.51 Million ≈ $34.50 Million |
+13.20pp |
| 2003-12-31 | 71.02% | €14.47 Million ≈ $16.92 Million |
€20.38 Million ≈ $23.82 Million |
-- |
About Innate Pharma
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated t… Read more